A single dose of 1.5-mg levonorgestrel and a single low dose of 10-mg mifepristone are effective methods for emergency contraception.
Ventilation/perfusion scanning appears to be safe and effective, at least in ruling out significant clinical pulmonary embolism in pregnant patients. However, prospective studies over longer time periods should be undertaken to validate these conclusions.
The FDA has mandated a Black Box warning for all estrogen and estrogen/progestin products for use by postmenopausal women. The new warnings are based on analysis of data from the Womens Health Initiative (WHI) study that was published July 2002.
Will your facility soon be implementing the OraQuick Rapid HIV-1 Antibody Test? If so, there are several resources to help you get up to speed in offering this new service.
While U.S. abortion rates are dropping, particularly among teens, the decline is not equally shared among all women. Rates have increased among those who are economically disadvantaged, according to just-published research from the New York City-based Alan Guttmacher Institute (AGI).
Get set to add more generic oral contraceptives (OCs) to your list of available birth control options as Corona, CA-based Watson Pharmaceuticals is rolling out its brand equivalents of Ortho-Cyclen and Ortho-Novum 7/7/7, two popular pills originally developed by Raritan, NJ-based Ortho-McNeil Pharmaceutical.
Put syphilis detection on your radar screen: Overall rates of primary and secondary syphilis have increased slightly for the first time in more than a decade, according to a new report from the Atlanta-based Centers for Disease Control and Prevention (CDC).1
How many times have you tested patients to determine their HIV status, never to see them return for the test results? Get ready for that scene to change; the Food and Drug Administrations (FDA) recent approval of a new test designed to detect HIV-1 antibodies in fingerstick whole blood samples will allow you to deliver the results in about 20 minutes.
What if you could offer your patients a vaccine for protection against human papillomavirus (HPV), a sexually transmitted disease (STD) that can cause genital warts and cervical cancer? Just-published results from a randomized double-blind study indicates that an investigational vaccine developed by West Point, PA-based Merck & Co. reduced the incidence of human papillomavirus type 16 (HPV 16) infection in 100% of women who previously had not been infected with the STD.
